BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

911 related articles for article (PubMed ID: 34373557)

  • 21. A novel immune-related long non-coding RNA signature improves the prognosis prediction in the context of head and neck squamous cell carcinoma.
    Chen L; Cai Z; Lyu K; Cai Z; Lei W
    Bioengineered; 2021 Dec; 12(1):2311-2325. PubMed ID: 34167440
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Single-Cell Transcriptome Analysis Reveals Different Immune Signatures in HPV- and HPV + Driven Human Head and Neck Squamous Cell Carcinoma.
    Li S; Wang Y; Sun R; Franceschi D; Pan H; Wei C; Ogbuehi AC; Lethaus B; Savkovic V; Gaus S; Zimmerer R; Ziebolz D; Schmalz G; Jiang X
    J Immunol Res; 2022; 2022():2079389. PubMed ID: 36157879
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy.
    Hanoteau A; Newton JM; Krupar R; Huang C; Liu HC; Gaspero A; Gartrell RD; Saenger YM; Hart TD; Santegoets SJ; Laoui D; Spanos C; Parikh F; Jayaraman P; Zhang B; Van der Burg SH; Van Ginderachter JA; Melief CJM; Sikora AG
    J Immunother Cancer; 2019 Jan; 7(1):10. PubMed ID: 30646957
    [TBL] [Abstract][Full Text] [Related]  

  • 24. High expression of CLEC10A in head and neck squamous cell carcinoma indicates favorable prognosis and high-level immune infiltration status.
    Zou M; Wu H; Zhou M; Xiao F; Abudushalamu G; Yao Y; Zhao F; Gao W; Yan X; Fan X; Wu G
    Cell Immunol; 2022 Feb; 372():104472. PubMed ID: 35093731
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Immune-checkpoint molecules on regulatory T-cells as a potential therapeutic target in head and neck squamous cell cancers.
    Suzuki S; Ogawa T; Sano R; Takahara T; Inukai D; Akira S; Tsuchida H; Yoshikawa K; Ueda R; Tsuzuki T
    Cancer Sci; 2020 Jun; 111(6):1943-1957. PubMed ID: 32304268
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Myeloid cell-targeted STAT3 inhibition sensitizes head and neck cancers to radiotherapy and T cell-mediated immunity.
    Moreira D; Sampath S; Won H; White SV; Su YL; Alcantara M; Wang C; Lee P; Maghami E; Massarelli E; Kortylewski M
    J Clin Invest; 2021 Jan; 131(2):. PubMed ID: 33232304
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The prognostic value of TMB and the relationship between TMB and immune infiltration in head and neck squamous cell carcinoma: A gene expression-based study.
    Zhang L; Li B; Peng Y; Wu F; Li Q; Lin Z; Xie S; Xiao L; Lin X; Ou Z; Cai T; Rong H; Fan S; Li J
    Oral Oncol; 2020 Nov; 110():104943. PubMed ID: 32919362
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Identification and validation of a prognostic signature of autophagy, apoptosis and pyroptosis-related genes for head and neck squamous cell carcinoma: to imply therapeutic choices of HPV negative patients.
    Nan Z; Dou Y; Chen A; Wang K; Sun J; Meng Z; Neckenig M; Ai D; Liu S; Dong Z; Ma C; Cheng Y; Qu X
    Front Immunol; 2022; 13():1100417. PubMed ID: 36703967
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The head and neck cancer immune landscape and its immunotherapeutic implications.
    Mandal R; Şenbabaoğlu Y; Desrichard A; Havel JJ; Dalin MG; Riaz N; Lee KW; Ganly I; Hakimi AA; Chan TA; Morris LG
    JCI Insight; 2016 Oct; 1(17):e89829. PubMed ID: 27777979
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Immune-related miRNA signature identifies prognosis and immune landscape in head and neck squamous cell carcinomas.
    Ma B; Li H; Qiao J; Meng T; Yu R
    Biosci Rep; 2020 Nov; 40(11):. PubMed ID: 33111959
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A digital score of tumour-associated stroma infiltrating lymphocytes predicts survival in head and neck squamous cell carcinoma.
    Shaban M; Raza SEA; Hassan M; Jamshed A; Mushtaq S; Loya A; Batis N; Brooks J; Nankivell P; Sharma N; Robinson M; Mehanna H; Khurram SA; Rajpoot N
    J Pathol; 2022 Feb; 256(2):174-185. PubMed ID: 34698394
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tissue-resident memory T cells correlate with the inflammatory tumor microenvironment and improved prognosis in head and neck squamous cell carcinoma.
    Ida S; Takahashi H; Kawabata-Iwakawa R; Mito I; Tada H; Chikamatsu K
    Oral Oncol; 2021 Nov; 122():105508. PubMed ID: 34507204
    [TBL] [Abstract][Full Text] [Related]  

  • 33. HPV infection related immune infiltration gene associated therapeutic strategy and clinical outcome in HNSCC.
    Zeng H; Song X; Ji J; Chen L; Liao Q; Ma X
    BMC Cancer; 2020 Aug; 20(1):796. PubMed ID: 32831060
    [TBL] [Abstract][Full Text] [Related]  

  • 34. High Abundance of Intratumoral γδ T Cells Favors a Better Prognosis in Head and Neck Squamous Cell Carcinoma: A Bioinformatic Analysis.
    Lu H; Dai W; Guo J; Wang D; Wen S; Yang L; Lin D; Xie W; Wen L; Fang J; Wang Z
    Front Immunol; 2020; 11():573920. PubMed ID: 33101298
    [TBL] [Abstract][Full Text] [Related]  

  • 35. TPPP3 Associated with Prognosis and Immune Infiltrates in Head and Neck Squamous Carcinoma.
    Yang Z; Li X; Li J; Su Q; Qiu Y; Zhang Z; Zhang L; Mo W
    Biomed Res Int; 2020; 2020():3962146. PubMed ID: 33083464
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
    Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Expression of immune response biomarkers (PD‑L1, p16, CD3+ and CD8+ TILs) in recurrent head and neck squamous cell carcinoma within previously irradiated areas.
    Pflumio C; Thomas J; Salleron J; Faivre JC; Borel C; Dolivet G; Sastre-Garau X; Geoffrois L
    Oncol Rep; 2021 Mar; 45(3):1273-1283. PubMed ID: 33432367
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of Immune Subtypes for Predicting the Prognosis of Patients in Head and Neck Squamous Cell Carcinoma.
    Sun J; Fang G; Zuo Z; Yu X; Xue L; Li C; Li S
    Technol Cancer Res Treat; 2021; 20():15330338211045823. PubMed ID: 34657509
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Microenvironment of Head and Neck Cancers: Papillomavirus Involvement and Potential Impact of Immunomodulatory Treatments.
    Outh-Gauer S; Morini A; Tartour E; Lépine C; Jung AC; Badoual C
    Head Neck Pathol; 2020 Jun; 14(2):330-340. PubMed ID: 32124416
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Characterization of the tumor immune microenvironment in human papillomavirus-positive and -negative head and neck squamous cell carcinomas.
    Succaria F; Kvistborg P; Stein JE; Engle EL; McMiller TL; Rooper LM; Thompson E; Berger AE; van den Brekel M; Zuur CL; Haanen J; Topalian SL; Taube JM
    Cancer Immunol Immunother; 2021 May; 70(5):1227-1237. PubMed ID: 33125511
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 46.